{{Rsnum
|rsid=45445694
|Orientation=plus
|Orientation=plus
|Chromosome=18
|position=657646
|Gene=TYMS
|Assembly=GRCh37.p2
|GenomeBuild=37.2
|dbSNPBuild=134
|Gene_s=C18orf56,TYMS
}}{{PharmGKB
|RSID=rs45445694
|Name_s=TYMS:*2 (2, 28-bp tandem repeats located in the TS enhancer region of 5'UTR)
|Gene_s=C18orf56, TYMS
|Feature=Intron, Intron
|Evidence=PubMed ID:15457444
|Annotation=Rheumatoid arthritis patients taking methotrexate (MTX) >3 months who carry the TYMS or TSER (TYMS enhancer region) *2/*2 (2, 28-bp repeat) genotype showed lower disease activity assessment as assessed by the physician (p = 0.049), lower patient's assessment of disease activity (p = 0.06), and less difficulty with physical tasks (p = 0.05) compared with carriers of a third 28-bp repeat (TSER*3/*3 and TSER*2/*3 combined); and a pharmacogenetic index of the combined variant alleles for MTX pathway gene variants, TYMS *2, ATIC 347C>G (116Ser), and SLC19A1 (RFC-1) 80A>G (27Arg), was associated with less tender joints (p = 0.012), less swollen joints (p = 0.004), less physician-assessed disease activity (p = 0.0004), and less patient-assessed difficulty with physical tasks (p = 0.001). The TYMS*3 allele is designated rs34743033.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA165106806
}}
{{PMID Auto
|PMID=22825513
|Title=Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer
}}{{PMID Auto
|PMID=22388795
|Title=Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.
}}